Literature DB >> 6303713

Current therapy of pulmonary and disseminated fungal diseases.

A M Stamm, W E Dismukes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6303713     DOI: 10.1378/chest.83.6.911

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  7 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

3.  Rhinocerebral invasive aspergillosis.

Authors:  I Tyagi; H C Taneja
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1998-01

4.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Authors:  P F Troke; R J Andrews; K W Brammer; M S Marriott; K Richardson
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.

Authors:  V Nagappan; D Boikov; J A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

6.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  The lung in paracoccidioidomycosis: new insights into old problems.

Authors:  Andre Nathan Costa; Gil Benard; Andre Luis Pereira Albuquerque; Carmem Lucia Fujita; Adriana Satie Kono Magri; João Marcos Salge; Maria Aparecida Shikanai-Yasuda; Carlos Roberto Ribeiro Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2013-04       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.